Drugs from bugs tops list of LAB282’s first round of grants
LAB282, the £13m drug discovery partnership for Oxford University, has made its first wave of awards, backing projects targeting cardiovascular and infectious diseases.
Launched last year as a partnership between the University, Evotec and Oxford Sciences Innovation, LAB282 aids the rapid translation of research outputs into new drug discovery and development programmes. It draws on expertise provided by Evotec and combines that with pre-clinical proof-of-concept grant funding to accelerate projects into a position where they can be commercialised and scaled up efficiently and effectively.
Read more (Oxford University Innovation Website)